GeNeuro Completes Enrollment in Phase 2 Trial Testing Temelimab in MS multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
4.5 (28)
The 2020 Barancik Prize for Innovation in MS Research has been awarded to neuroscientist Dwight E. Bergles, PhD, a Johns Hopkins University professor, for his work in understanding the function of brain cells in multiple sclerosis (MS).
This international prize awards $100,000 to the recipient.
Administered by the National MS Society, the prize seeks to “recognize and encourage exceptional innovation and originality in scientific research” into the causes and potential treatments for multiple sclerosis.
Myelin, the fat-rich substance that wraps around nerve fibers (axons), works to insulate and increase the velocity of signals relayed by nerve cells. Myelin loss is the underlying cause of diseases like MS.
4.3 (7)
The MS Society in the U.K. is hoping to raise £3.7 million ($5.2 million) to fund research aimed at developing new treatments for multiple sclerosis (MS).
The funds will support research at the Society’s Centers of Excellence in Edinburgh and Cambridge over five years.
“Our top priority is finding treatments that slow or stop MS for everyone,” Emma Gray, PhD, assistant director of research at the MS Society, said in a press release. “The work happening in Cambridge and Edinburgh is inventive, innovative and incredibly exciting, and will be vital to help us reach our goal.”
MS is caused by immune cells attacking the body’s own myelin, a fatty insulation that covers the long branches, called axons, that extend from nerve cells. When myelin is destroyed a process called demyelination the connections between neurons become defective and MS symptoms arise.
4.1 (14)
BioLiberty, a Scottish biotech startup, has developed a robotic glove that uses artificial intelligence (AI) to improve the hand grip in people with muscle weakness due to multiple sclerosis (MS) and other conditions.
The technology may be closer to entering people’s homes now that the startup has secured support from the Edinburgh Business School’s Incubator, based at Heriot-Watt University, in Scotland.
“Up to now, we’ve funded the company from business competition awards so being accepted into the Edinburgh Business School Incubator program is a huge boost,” Ross O’Hanlon, one of the four engineering graduates who founded BioLiberty, said in a press release.